<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3454">
  <stage>Registered</stage>
  <submitdate>31/01/2012</submitdate>
  <approvaldate>31/01/2012</approvaldate>
  <nctid>NCT01525212</nctid>
  <trial_identification>
    <studytitle>Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients</studytitle>
    <scientifictitle>Double-Blinded, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of BMS-929075 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>AI457-002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic Hepatitis C</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - BMS-929075
Treatment: drugs - BMS-929075
Treatment: drugs - BMS-929075
Treatment: drugs - BMS-929075
Treatment: drugs - Placebo matching BMS-929075
Treatment: drugs - Placebo matching BMS-929075

Experimental: Arm 1: BMS-929075 (= 25 mg) OR Placebo matching BMS-929075 - 

Experimental: Arm 2: BMS-929075 (= 100 mg) OR Placebo matching BMS-929075 - 

Experimental: Arm 3: BMS-929075 (= 400 mg) OR Placebo matching BMS-929075 - 

Experimental: Arm 4: BMS-929075 (= 800 mg) OR Placebo matching BMS-929075 - 


Treatment: drugs: BMS-929075
Oral Suspension, = 25 mg, Once daily, 3 days

Treatment: drugs: BMS-929075
Oral Suspension, = 100 mg, Once daily, 3 days

Treatment: drugs: BMS-929075
Oral Suspension, = 400 mg, Once daily, 3 days

Treatment: drugs: BMS-929075
Oral Suspension, (= 800 mg, Once daily) OR (= 400 mg, Twice daily), 3 days

Treatment: drugs: Placebo matching BMS-929075
Oral Suspension, 0 mg, Once daily, 3 days

Treatment: drugs: Placebo matching BMS-929075
Oral Suspension, 0 mg, (Once daily for = 800 mg group) OR (Twice daily for = 400 mg group), 3 days

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>HCV RNA level on Day 4</outcome>
      <timepoint>Within 4 days after the first dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum decrease from baseline in plasma HCV RNA levels during the period from Day 1 to Day 28</outcome>
      <timepoint>Days 1-28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time course of the change from baseline in plasma HCV RNA levels and the time of maximum decrease during the period of Day 1 through Day 28</outcome>
      <timepoint>Days 1-28</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests</outcome>
      <timepoint>Days 1-28 (with SAE from screening to Day 30)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum observed plasma concentration (Cmax) of BMS-929075 derived from plasma concentration versus time</outcome>
      <timepoint>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minimum observed plasma concentration (Cmin) of BMS-929075 derived from plasma concentration versus time</outcome>
      <timepoint>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Trough observed plasma concentration (Ctrough) of BMS-929075 derived from plasma concentration versus time</outcome>
      <timepoint>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time of maximum observed plasma concentration (Tmax) of BMS-929075 derived from plasma concentration versus time</outcome>
      <timepoint>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-929075 derived from plasma concentration versus time</outcome>
      <timepoint>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma half-life (T-HALF) of BMS-929075 derived from plasma concentration versus time</outcome>
      <timepoint>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Protein Binding (PB) of BMS-929075 derived from plasma concentration versus time</outcome>
      <timepoint>Day 3 (0h and 2h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fraction of free drug in plasma (fu) of BMS-929075 derived from plasma concentration versus time</outcome>
      <timepoint>Day 1 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h), Day 2, and Day 3 (0h, 0.5h, 1 h, 1.5h, 2h, 3h, 4h, 6h, 8h, 12h,24h, 36h, 48h and 72h)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The relationship between antiviral activity and measures of exposure to BMS-929075</outcome>
      <timepoint>Days 1-6</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men and women, ages 18 to 65 years, inclusive

          -  Subjects who are naive to HCV treatment, defined as no previous exposure to an
             Interferon (IFN), Ribavirin (RBV); or any HCV-specific direct acting antiviral or
             experimental therapy

          -  HCV genotype 1a or 1b only

          -  HCV RNA viral load of = 100,000 IU/mL

          -  Have one of the following: i) Documented Fibrotest score of = 0.72 and AST to platelet
             ratio index (APRI) = 2; or ii) Documented liver biopsy within 12 months preceding Day
             1 showing absence of cirrhosis

          -  Body Mass Index (BMI) of 18.0 to 35.0 kg/m2, inclusive</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any significant acute or chronic medical illness

          -  History of adrenal gland disease, including but not limited to adrenal insufficiency
             or Cushing's syndrome

          -  Current or recent (within 3 months of study drug administration) gastrointestinal
             disease

          -  Any major surgery within 4 weeks of study drug administration

          -  Any gastrointestinal surgery that could impact upon the absorption of study drug

          -  Positive for hepatitis B surface antigen (HBsAg)

          -  Positive for Human Immunodeficiency Virus (HIV) -1 and/or -2 antibodies

          -  Smoking &gt; 10 cigarettes per day

          -  Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) &gt; 5x upper limit of
             normal (ULN)

          -  Total Bilirubin = 1.5x ULN

          -  Hemoglobin &lt; 10 g/dL

          -  Platelets &lt; 75,000 cell/µL

          -  ALC (absolute lymphocyte count) &lt; 1000 cell/µL

          -  Creatinine clearance (as estimated by method of Cockcroft and Gault) less than 60
             mL/min</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/04/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>0</actualsamplesize>
    <recruitmentstatus>Withdrawn</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2013</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC</recruitmentstate>
    <hospital>Local Institution - Herston</hospital>
    <hospital>Local Institution - Adelaide</hospital>
    <hospital>Local Institution - Melbourne</hospital>
    <postcode>4006 - Herston</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol-Myers Squibb</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the change from baseline in HCV Ribonucleic acid
      (RNA) on Day 4 following three days of dosing with BMS-929075 in chronically genotype subtype
      1a and 1b HCV infected subjects</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01525212</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bristol-Myers Squibb</name>
      <address>Bristol-Myers Squibb</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>